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INTRODUCTION
It has been reported that G-CSF administration im-
proves cardiac function by reducing the area of the
infarct, leading to a decreased mortality in a rat myo-
cardial infarction model. In 2001, inhibition of postin-
farction cardiac remodeling, improvement in cardiac
function, and a reduction in the mortality rate by
the administration of granulocyte colony-stimulating
factor (G-CSF) and stem cell factor (SCF) were re-
ported (1).
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ders by ischemia reperfusion was studied.Methods : Myocardial infarction model rats were
produced by ligation of the left anterior descending coronary artery in 12-week-old Wis-
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a myocardial histopathological diagnosis were carried out and the results compared among
the groups. Results : No significant differences were found in the proportion of the re-
sidual heart muscle in the infarct lesion, myocardial wall thickness, or left ventricular
ejection fraction between the MI-G and MI-C groups. In contrast, the infarct area, myocar-
dial wall thickness, and left ventricular ejection fraction were significantly improved in
the R-G group compared to the R-C group (p<0.05). Conclusions : Any inhibitory effect of
G-CSF on the infarct lesion was found in the myocardial infarction reperfusion model
rat, but only a small effect was found in rats with a complete ligation-induced myocardial
infarction. The findings in the present study, therefore, suggest that G-CSF is effective for
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In the present study, myocardial infarction model
rats were prepared by ligation of the left anterior
descending coronary artery, and G-CSF was admin-
istered to rats with a complete ligation and with
reperfusion of the ligation-induced infarction. In the
present study, the G-CSF effect for treating cardiac
muscle cell disorders by ischemia reperfusion was
studied.
METHODS
1) Myocardial infarction and the reperfusion rat
model
After the induction of general anesthesia by a in-
traperitoneal injection of 35 mg/kg pentobarbital
(Nembutal, Dainippon-Sumitomo Pharmaceutical
Co., Ltd., Osaka, Japan) in Wistar rats (12-weeks-
old, 250 g body weight), a midline skin incision was
made in the anterior cervical region, and the ster-
nohyoid muscle was divided in the middle to expose
the trachea. Half circumference of an inter-tracheal
cartilage region was incised, and an artificial respi-
ration Y-piece (2.0Ф) was inserted and fixed by su-
turing. A respirator (SN-480-7, Shinano manufac-
turing Co., Ltd. Tokyo, Japan) was set to 1 ml/100
g body weight and a respiratory rate of 80 times/
min. The thorax was opened via the left 4-5th inter-
costal region, using a rib spreader (retractor, MY-
9454S, Matsuyoshi & Co., Ltd., Tokyo, Japan). Elec-
trocardiography (ECG) electrodes were attached
to the bilateral front legs and rear ankles with ECG
paste (Keratin cream, Fukuda Denshi, Tokyo, Japan),
and a limb-led ECG was recorded (LABO-SYSTEM
ZS-501, Fukuda ME, Tokyo, Japan). The retractor
was detached during the ECG recording.
Fig. 1 shows an example of a limb-lead ECG be-
fore and after ligation of the left anterior descending
coronary artery on thoracotomy under artificial res-
piration. No ST elevation was noted on the lead I
and II ECG before the ligation. Myocardial ischemia-
associated ST elevation was noted on the lead II
ECG after the ligation. The success of the ligation
of the anterior descending branch of the coronary
artery was confirmed, as evidenced by ST elevation
on the ECG in all rats.
The left anterior descending coronary artery
was visually confirmed, and ligated using a suturing
needle with thread (vascular round needle, No. 008
mm, black braid silk No. 6-0, Natsume Seisakusho,
Tokyo, Japan). After ligation, ST elevation was con-
firmed on ECG, and 12 rats without removal of the
ligation (complete ligation group ; MI group) and
12 rats in which the ligation was removed for reper-
fusion 30 minutes after ligation (reperfusion group ;
R group) were prepared. For reperfusion of the coro-
nary artery, a 0.6-mm rubber thread was placed
under the ligation thread so that the ligation thread
could be easily cut. The opened thorax was closed
by suturing with 2.0 silk thread (alfresa, Tokyo, Ja-
pan), and the rats were maintained at the animal
experiment facility of The University of Tokushima.
The present study was approved by The Univer-
sity of Tokushima Animal Experiment Committee,
and performed in accordance with The University
of Tokushima Guidelines for Animal Experiments
(enforced on June 30, 1989, revised on April 15,
2005) in conformity with the Law concerning Ani-
mal Protection and Management (Law No. 105 in
1973, partially revised on December 22, 1999) and
the Standards concerning Animal Maintenance and
Storage for Animal Experiments (Notice from the
Prime Minister’s Office No. 6, March 1980, partially
revised on May 28, 2002).
2) Grouping of animals for the administration of
G-CSF and physiological saline
The MI and R groups were divided into two groups
that received an intraperitoneal injection of 0.5 ml
of physiological saline daily for 5 days (MI-C and R-
C groups, n=6 each) and groups that received an
intraperitoneal injection of recombinant G-CSF (nar-
tograstim, Neu-up, Kyowa Hakko Industry Ltd.,
Tokyo, Japan) at 100 μg/kg/day (single dose : 25
μg of G-CSF dissolved in 0.5 ml of physiological
saline) daily for 5 days (MI-G and R-G groups, n=6
each). G-CSF was administrated 60 min after the
preparation of the myocardial infarction.
3) Echocardiography
For the ultrasonic instrument and probe, an Aplio
Fig. 1 Example of a limb-lead ECG before and after ligation of
the left anterior descending coronary artery on thoracotomy under
artificial respiration.
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80 (Toshiba Medical Systems SSA-770A) and a 10
MHz linear transducer were used. Echocardiogra-
phy was performed by the M and B modes 4 weeks
after the administration of G-SCF or saline in the
MI-G, MI-C, R-G, and R-C groups, and the left ven-
tricular end-diastolic dimension (LVDd), left ven-
tricular diameter at end systole (LVDs), interven-
tricular septum thickness (LVST) and left ventricu-
lar posterior wall thickness (LVPWT) were calcu-
lated. These data were stored on a hard disc. For
echocardiography, the minimum dose of pentobar-
bital (0.2 ml) was intraperitoneally injected for an-
esthesia. When the depth of anesthesia was insuf-
ficient, an additional 0.1 ml was administered. LVDd,
the proportion of the left ventricular wall thickness
([infarct wall thickness]/[non-infarct wall thick-
ness]), and the left ventricular ejection fraction (EF)
were compared among the MI-G, MI-C, R-G, and
R-C groups after 4 weeks. Echocardiography was
measured under these conditions ; room tempera-
ture, 20 degrees Celsius and a heart rate between
300 to 400/min.
4) Histological examination
After echocardiography, the animals were sacri-
ficed by an intraperitoneal injection of 2 ml of pen-
tobarbital (overdose anesthesia). The heart was ex-
cised, a portion was fixed with 10% formalin, and
paraffin-embedded sections were prepared. These
sections were stained with hematoxylin-eosin (HE)
and Azan for a histological examination. To meas-
ure the infarct area, one slice of the central part of
the ventricle, was manually measured using ImageJ
(Image Processing and Analysis in Java, Wayne Ras-
band, National Institutes of Health, USA). The in-
farct area ratio (%) on Azan staining were compared
among the MI-G, MI-C, R-G, and R-C groups.
5) Statistical analysis
The measured values are presented as the means
± standard deviation (SD) and were analyzed us-
ing the unpaired t-test. P<0.05 was regarded as sig-
nificant.
RESULTS
1) Echocardiography findings
Fig. 2 shows examples of echocardiography find-
ings for the MI-G (panel a), MI-C (panel b), R-G
(panel c), and R-C (panel d) groups. In the MI-G
group (panel a), the anterior wall was thinned on the
B mode, and akinetic motion was noted on the M
mode. In the MI-C group (panel b), thinning of the
anterior wall on the B mode was milder than that in
the MI-G group, and the anterior wall motion re-
mained hypokinetic on the M mode. In the R-G
group (panel c), the thickness of the anterior wall
was maintained on the B mode, and no abnormal
wall motion was noted. In the R-C group (panel d),
the anterior wall thickness was normal on the B
mode, and the anterior wall motion was normal on
the M mode.
Table 1 shows a comparison of the echocardiogra-
phy findings among the MI-G, MI-C, R-G, and R-C
groups. LVDd increased in the MI-G (7.1 ± 1.4 mm)
and MI-C (7.1 ± 1.1 mm) groups, showing no sig-
nificant difference between the groups. In contrast,
LVDd in the R-G group (3.6 ± 0.4 mm) was signifi-
cantly smaller than that in the R-C group (4.2 ±
0.8 mm).
LVDs showed a tendency similar to that for LVDd.
LVDs increased in the MI-G (6.0 ± 1.2 mm) and
MI-C (6.1 ± 1.4 mm) groups, showing no significant
difference between the groups. In contrast, LVDs
in the R-G group (1.4 ± 0.4 mm) was significantly
smaller than that in the R-C group (2.1 ± 0.6 mm).
The proportion of left ventricular wall thickness
(infarct wall thickness/non-infarct wall thickness)
was 0.5 ± 0.1 and 0.4 ± 0.2 in the MI-G and MI-C
groups, respectively, showing thinning of the inter-
ventricular septum, and no significant difference was
Fig. 2 Examples of echocardiography findings for the MI-G
(panel a), MI-C (panel b), R-G (panel c), and R-C (panel d)
groups.
LVDd, left ventricular end-diastolic dimension ; LVDs, left ven-
tricular diameter at end systole ; IVST, interventricular septum
thickness ; LVPWT, left ventricular posterior wall thickness ;
EF, left ventricular ejection fraction.
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noted between the groups. In contrast, the propor-
tion for the R-G group (0.9 ± 0.2) was significantly
higher than that for the R-C group (0.7 ± 0.4).
EF was markedly decreased in the MI-G (38.6 ±
10.2%) and MI-C (35.4 ± 8.8%) groups, showing no
significant difference between the groups. In con-
trast, sufficient EF was maintained in the R-G (64.4
± 12.4%) and R-C (52.8 ± 10.8%) groups, and the EF
in the R-G group was significantly higher than that
in the R-C group.
2) Histological findings
Fig. 3 shows a comparison of Azan-stained ven-
tricular cross sections among the MI-G (panel a),
MI-C (panel b), R-G (panel c), and R-C (panel d)
groups. In the MI-G and MI-C groups, blue-stained
collagen fibers, considered to be the fibrosed region
of myocardial infarction-associated necrosis, were
noted. In contrast, the ventricular wall thickness was
relatively maintained in the R-G and R-C groups, but
collagen fibers were noted in spaces between car-
diomyocytes.
Fig. 4 shows the histological findings on HE and
Azan staining for the MI-G (panel a), MI-C (panel
b), R-G (panel c), and R-C (panel d) groups. In the
MI-C group, decreased cytoplasmic muscle fibers
and the formation of many fissures between the
heart muscle fibers were noted on HE staining. On
Azan staining, numerous blue-stained collagen fi-
bers were noted. In the MI-G group, the decrease
in cytoplasmic muscle fibers was less than that in the
MI-C group, but numerous fissures were formed
between the heart muscle fibers. Azan staining
showed numerous blue-stained collagen fibers, as
in the MI-C group. In R-G group, the cytoplasmic
muscle fibers stained red with eosin were homoge-
nously maintained on HE staining, and no fissure
formation along cardiomyocytes was noted. No blue-
Fig. 3 Comparison of Azan-stained ventricular cross sections
among the MI-G (panel a), MI-C (panel b), R-G (panel c), and
R-C (panel d) groups.
Fig. 4 Histological findings on HE and Azan staining for the
MI-G (panel a), MI-C (panel b), R-G (panel c), and R-C (panel d)
groups.
Table 1 Comparison of the echocardiography findings among
the MI-G, MI-C, R-G, and R-C groups
group MI-G MI-C R-G R-C
LVDd (mm) 7.1±1.4 7.1±1.1 3.6±0.4＊ 4.2±0.8
LVDs (mm) 6.0±1.2 6.1±1.4 1.4±0.4＊ 2.1±0.6
IVST/LVPWT 0.5±0.1 0.4±0.2 0.9±0.2＊ 0.7±0.4
EF(%) 38.6±10.2 35.4±8.8 64.4±12.4＊ 52.8±10.8
LVDd, left ventricular end-diastolic dimension ; LVDs, left ven-
tricular diameter at end systole ; IVST, interventricular septum
thickness ; LVPWT, left ventricular posterior wall thickness ; EF,
left ventricular ejection fraction.
mean ± SD, ＊p<0.05 vs R-C group
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stained collagen fibers were noted on Azan staining.
In the R-C group, the cytoplasmic muscle fibers were
stained red with eosin, numerous fissures were
formed along the heart muscle fibers, and the in-
terstitium was widely infiltrated by inflammatory
cells dominated by monocytes on HE staining. Blue-
stained collagen fibers were noted on Azan stain-
ing, but to a lesser degree than that noted in the
MI-G and MI-C groups.
Fig. 5 shows the infarct area ratio (%). The infarct
area ratio (%) was high in the MI-G (26.9 ± 6.1%)
and MI-C (25.2 ± 6.3%) groups, showing no signifi-
cant difference between the groups. In contrast, the
ratio was significantly lower in the R-G group (2.6
± 1.0%) than in the R-C group (6.2 ± 1.1%).
DISCUSSION
G-CSF administration did not change the infarct
area ratio, left ventricular wall thickness, or left ven-
tricular ejection fraction in rats with a complete liga-
tion of the coronary artery, whereas G-CSF signifi-
cantly reduced the infarct area ratio and left ven-
tricular thickness and improved the left ventricu-
lar ejection fraction in rats with reperfusion of the
ligation-induced infarction.
The areas of the myocardial infarction by ligation
release and complete ligation are different in this
animal model. Moreover, myocardial infarction is
caused by different mechanisms, because the MI-
C group and R-C group are coagulative necrosis and
ischemia reperfusion models, respectively. The find-
ings in the present study, therefore, suggest that
G-CSF is effective for treating cardiac muscle cell
disorders by ischemia reperfusion.
In recent years with the marked advances in re-
generative medicine, the early clinical application of
myocardial regenerative treatment would be ex-
pected to be promising for increasing myocardial
contractility. Regenerative medicine for myocardial
infarctions is roughly divided into cellular treatments
aimed at vascular regeneration (2-4) and myocardial
regeneration in which cells are transplanted in the
infarct region of the heart muscle (5, 6). As a clini-
cal application of vascular regeneration, G-CSF ad-
ministration has been reported to significantly in-
crease collateral flow in patients with coronary ar-
terial disease, showing a vascularization effect (7).
Various approaches for myocardial regeneration
have been investigated, and studies of regenerated
cardiomyocytes, pluripotent stem cells, and skele-
tal myoblasts using embryonic and bone marrow so-
matic stem cells as tools are currently underway.
Myocardial sheets have been developed by tissue
engineering groups (8-11). No regeneration of car-
diomyocytes or arterialization in the border zone was
found in this experiment and this does not prove
that G-CSF does not have a regenerative effect.
The possibility of treatment with cytokines, such
as G-CSF, during the acute phase of a myocardial
infarction to induce the migration of stem cells to
the infarct region and regeneration of the injured
myocardial region has been reported (12). Orlic, et
al. (1) reported that the concomitant administra-
tion of G-CSF and stem cell factor mobilized bone
marrow cells to the infarct tissue at a high rate in a
mouse acute myocardial infarction model, and that
these cells regenerated cardiomyocytes and vascu-
lar endothelial cells, reducing the myocardial infarct
size by 40% and the mortality rate by 68%.
Minatoguchi, et al. (13) reported that the admini-
stration of G-CSF alone at a dose close to the typi-
cal clinical dose after the preparation of a myocar-
dial infarction had a therapeutic effect, in which G-
CSF significantly increased cardiomyocytes, vascu-
lar endothelium, vascular smooth muscle, and my-
ofibroblasts, which may have reduced the infarct
area, inhibited cardiac remodeling, and improved
cardiac function, but very few bone marrow-derived
cardiomyocytes were found (13, 14), suggesting that
G-CSF not only promotes myocardial regeneration
by the migration of bone marrow cardiomyocytes
but also directly protects existing cardiomyocytes.
Harada, et al. (15) also reported that G-CSF pro-
motes survival of cardiac myocytes and prevents
left ventricular remodeling after myocardial infarc-
tion through the functional communication between
cardiomyocytes and noncardiomyocytes. Therefore,
in this study, the mechanism of G-CSF effect for
treating cardiac muscle cell disorders by ischemia
reperfusion is not coronary arteries patency, but the
direct action on cardiomyocytes after myocardial in-
Fig. 5 Infarct area ratio (%).
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farction.
G-CSF is clinically used as a therapeutic drug for
the treatment of leukemia and leucopenia after can-
cer chemotherapy. G-CSF has various actions, and
the major actions are to promote the proliferation
and differentiation of bone marrow precursor cells
and to immobilize bone marrow stem cells. G-CSF
administration promotes the induction of stem cells
in the bone marrow and their release into the cir-
culation in rats.
Since G-CSF can be readily administere, such as
by subcutaneous and intravenous injection, it is less
invasive for patients. In addition, fewer ethical prob-
lems are involved because it mobilizes the patient’s
own cells. Thus, G-CSF may become a new thera-
peutic strategy for treating myocardial infarctions in
the near future (16). However, it has been reported
that the stent re-stenosis rate increased after G-SCF
administration, although it improved cardiac func-
tion after coronary arterial stenting for myocardial
infarction (17).
In the present study, G-CSF was administered in-
traperitoneally, and a sufficient effect may be pro-
duced by intravenous administration, if the blood
vessel responsible for the infarction is patent, al-
though it cannot be directly injected into the heart
muscle. Because of these possible actions, no sig-
nificant differences were noted in the infarct area
ratio, left ventricular wall thickness, or left ventricu-
lar ejection fraction between the MI-G and MI-C
groups with a complete ligation of the coronary ar-
tery, whereas a significant reduction in the infarct
area and improvement of the left ventricular wall
thickness and left ventricular ejection fraction were
noted in R-G and R-C groups with reperfusion. Based
on these findings, G-CSF is effective for treating car-
diac muscle cell disorders by ischemia reperfusion.
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